Pembrolizumab after platinum-based chemotherapy for metastatic urothelial cancer: comparison between patients from a Dutch nationwide cohort and KEYNOTE-045

Pembrolizumab after platinum-based chemotherapy for metastatic urothelial cancer: comparison between patients from a Dutch nationwide cohort and KEYNOTE-045

Background and objective: Pending adoption of enfortumab-vedotin plus pembrolizumab in first-line setting, platinum-based chemotherapy remains the standard of care for patients with metastatic or locally advanced urothelial cancer (mUC). Second-line pembrolizumab may be offered to patients with dise...

Full description

Saved in:
Bibliographic Details
Main Authors: Anke Richters, Britt Suelmann, Mira Franken, Niven Mehra, Bart Rikhof, Hans Westgeest, Katja Aben, Debbie Robbrecht, Lambertus Kiemeney, Joost Boormans, Toine van der Heijden, Richard Meijer, Tom Arends, Saskia van der Meer, Filip Delaere, André Vis, Carl Wijburg, Ilze van Onna, Diederik Somford, Bart Wijsman, Thomas Kerkhofs, Joan van den Bosch, Annemarie Leliveld-Kors, Katja Goossens- van der Laan, Gerd-Jan Molijn, Luc Roelofs, Martijn Steffens, Tom Hermans, Marleen Duizer
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Cancer Treatment and Research Communications
Subjects:
Urothelial cancer
Bladder cancer
Immunotherapy
Pembrolizumab
Real-world data
Online Access:http://www.sciencedirect.com/science/article/pii/S2468294225000656
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2468294225000656

Similar Items